ClinVar Miner

Submissions for variant NM_000317.3(PTS):c.370G>T (p.Val124Leu)

gnomAD frequency: 0.00003  dbSNP: rs150726932
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 9
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Counsyl RCV000672207 SCV000797288 uncertain significance 6-Pyruvoyl-tetrahydrobiopterin synthase deficiency 2018-01-19 criteria provided, single submitter clinical testing
Illumina Laboratory Services, Illumina RCV000672207 SCV000915500 uncertain significance 6-Pyruvoyl-tetrahydrobiopterin synthase deficiency 2018-09-14 criteria provided, single submitter clinical testing The PTS c.370G>T (p.Val124Leu)missense variant has been reported in a single study in which it is found in a compound heterozygous state with a second missense variant in one individual with a mild presentation of 6-pyruvoyltetrahydropterin synthase deficiency (Dudesek et al. 2000). Control data are unavailable for this variant, which is reported at a frequency of 0.0001454 in the Latino population of the Genome Aggregation Database. Functional studies revealed that p.Val124Leu recombinant protein had no detectable PTPS enzyme activity in COS-1 cells. Based on the limited evidence, the p.Phe56Ile variant is classified as a variant of unknown significance but suspicious for pathogenicity for 6-pyruvoyltetrahydropterin synthase deficiency. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
Invitae RCV000672207 SCV000934117 pathogenic 6-Pyruvoyl-tetrahydrobiopterin synthase deficiency 2024-01-29 criteria provided, single submitter clinical testing This sequence change replaces valine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 124 of the PTS protein (p.Val124Leu). This variant is present in population databases (rs150726932, gnomAD 0.01%). This missense change has been observed in individual(s) with PTPS deficiency (PMID: 11388593, 27243974). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 556231). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Not Available"; PolyPhen-2: "Benign"; Align-GVGD: "Not Available". The leucine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. Experimental studies have shown that this missense change affects PTS function (PMID: 11388593). For these reasons, this variant has been classified as Pathogenic.
Baylor Genetics RCV000672207 SCV001163279 likely pathogenic 6-Pyruvoyl-tetrahydrobiopterin synthase deficiency 2024-03-25 criteria provided, single submitter clinical testing
Genome-Nilou Lab RCV000672207 SCV001712372 uncertain significance 6-Pyruvoyl-tetrahydrobiopterin synthase deficiency 2021-05-18 criteria provided, single submitter clinical testing
Ambry Genetics RCV002531311 SCV003738985 uncertain significance Inborn genetic diseases 2022-01-26 criteria provided, single submitter clinical testing The c.370G>T (p.V124L) alteration is located in exon 6 (coding exon 6) of the PTS gene. This alteration results from a G to T substitution at nucleotide position 370, causing the valine (V) at amino acid position 124 to be replaced by a leucine (L). Based on data from gnomAD, the T allele has an overall frequency of 0.007% (20/281996) total alleles studied. The highest observed frequency was 0.014% (5/35380) of Latino alleles. This alteration has been reported with a second alteration in PTS, in two patients with a mild form of 6-pyruvoyl-tetrahydropterin synthase deficiency (PTPS) (Dudesek, 2001; Yubero, 2016; Cortès-Saladelafont, 2018). This amino acid position is not well conserved in available vertebrate species. PTPS activity in fibroblast and red blood cells of the patient with p.L26F/p.V124L were low compared to controls (Dudesek, 2001). The in silico prediction for this alteration is inconclusive. Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.
Institute of Human Genetics, University of Leipzig Medical Center RCV000672207 SCV004812112 likely pathogenic 6-Pyruvoyl-tetrahydrobiopterin synthase deficiency 2024-03-04 criteria provided, single submitter clinical testing Criteria applied: PM3_STR,PM1_SUP,PM2_SUP,PP4
Laboratory of Medical Genetics, National & Kapodistrian University of Athens RCV000672207 SCV005051946 likely pathogenic 6-Pyruvoyl-tetrahydrobiopterin synthase deficiency 2024-02-01 criteria provided, single submitter curation
Natera, Inc. RCV000672207 SCV002078496 likely pathogenic 6-Pyruvoyl-tetrahydrobiopterin synthase deficiency 2020-12-22 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.